Cloudbreak Pharma Valuation Multiples

Cloudbreak Pharma is valued at $140M as of November 2026. In the last fiscal year, Cloudbreak Pharma EBITDA was ($68M).

Cloudbreak Pharma Overview

About Cloudbreak Pharma

Cloudbreak Pharma Inc is an innovation-driven clinical-stage ophthalmology biotechnology company dedicated to the development of novel and differentiated treatments. The company’s focus is on Meibomian Gland Dysfunction Associated Dry Eye Disease, Pterygium, Pinguecula, Glaucoma Filtration Surgery, Wet Age-Related Macular Degeneration, and Myopia Progression. Its drugs in pipeline include CBT-001, CBT-004, CBT-006, CBT-007, CBT-009, and CBT-011.


Founded

2020

HQ

United States

Employees

51

Financials (Last FY)

Revenue: -
EBITDA: ($68M)

EV

$102M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cloudbreak Pharma Financials

Cloudbreak Pharma reported last fiscal year revenue of - and negative EBITDA of ($68M).

In the same fiscal year, Cloudbreak Pharma generated ($68M) in EBITDA losses and had net loss of ($68M).


Cloudbreak Pharma P&L

In the most recent fiscal year, Cloudbreak Pharma reported revenue of - and EBITDA of ($68M).

Cloudbreak Pharma is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Cloudbreak Pharma
Last FY2025202620272028
EBITDA($68M)($68M)
Net Profit($68M)($68M)
Net Debt($39M)-

Financial data powered by Morningstar, Inc.

Cloudbreak Pharma Stock Performance

Cloudbreak Pharma has current market cap of $140M, and enterprise value of $102M.

Market Cap Evolution


Cloudbreak Pharma's stock price is $0.15.

Cloudbreak Pharma has an EPS (earnings per share) of $-0.07.

See more trading valuation data for Cloudbreak Pharma
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$102M$140M0.0%---$-0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cloudbreak Pharma Valuation Multiples

Cloudbreak Pharma trades at (1.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cloudbreak Pharma

Cloudbreak Pharma Financial Valuation Multiples

As of November 19, 2026, Cloudbreak Pharma has market cap of $140M and EV of $102M.

Cloudbreak Pharma has a P/E ratio of (2.1x).

Last FY2025202620272028
EV/EBITDA(1.5x)(1.5x)
EV/EBIT(0.9x)(0.9x)
P/E(2.1x)(2.1x)
EV/FCF(1.5x)(1.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cloudbreak Pharma Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cloudbreak Pharma Operational KPIs

Cloudbreak Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.

Access forward-looking KPIs for Cloudbreak Pharma
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$2.1M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cloudbreak Pharma Competitors

Cloudbreak Pharma competitors include Biosyent, Invivyd, Humacyte, Sutro Biopharma, Starpharma, PolyPid, Scancell, Biomm, IMBiologics and Atrium Therapeutics.

Most Cloudbreak Pharma public comparables operate across Biopharmaceuticals, Contract Research & Manufacturing and BioTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Biosyent$30M$8M4.5x2.8x16.0x11.4x
Invivyd$53M($50M)0.4x0.4x(0.4x)(0.1x)
Humacyte$2M($25M)69.1x37.0x(5.7x)-
Sutro Biopharma$102M($151M)0.1x0.2x(0.1x)-
Starpharma$8M($5M)16.2x14.2x(27.2x)(33.0x)
PolyPid-($32M)-23.1x(3.8x)-
Scancell-($24M)-150.8x(6.7x)(5.3x)
Biomm$47M$329K3.3x-468.3x-

This data is available for Pro users. Sign up to see all Cloudbreak Pharma competitors and their valuation data.

Start Free Trial

Cloudbreak Pharma VC Funding History

Before going public, Cloudbreak Pharma raised $171M in total equity funding, across 3 rounds.


Cloudbreak Pharma Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jan-22Series CYuejun Investment; ShenZhen GTJA Investment Group; CCB International; CDF-Capital; Yingke Capital; EFung Capital; Industrial Securities Capital; Guanzi Capital; Dyee Capital; Grand Pharmaceutical; CDH Investments$130M-Cloudbreak Therapeutics (also referred to as Cloudbreak Pharmaceutical) is a clinical-stage biotechnology company focused on ocular drug development. It completed a Series C funding round of $130 million on January 1, 2022, led by investors including CDH Investments, CCB International, CDF-Capital, DYEE Capital, EFung Capital, Grand Pharmaceutical, Guanzi Capital, Industrial Securities Capital, Shenzhen GTJA Investment Group, YINGKE PE, and Yuejun Investment. The proceeds from the Series C round are designated for advancing drug candidates through clinical trials, product registration, and commercialization efforts. Additional plans include building a GMP pilot production platform to meet international standards, enhancing production capacity, and strengthening team construction. As of this round, Cloudbreak Therapeutics had raised a total of $171.26 million across three funding rounds.
Apr-20Series BV-Capital; China Grand Pharmaceutical and Healthcare Holdings; BOC International Holdings$25M-Cloudbreak Therapeutics LLC closed a funding round on April 17, 2020, raising $25.44 million led by V Capital Equity Investment Co., Ltd., with participation from China Grand Pharmaceutical and Healthcare Holdings Limited, Bank of China Investment Management Co., Ltd., and Lumiere Fund. The transaction terms were amended prior to closing. Cloudbreak Pharma, likely related or successor entity, develops ophthalmic therapeutics including CBT-001 for diabetic macular edema, CBT-009, CBT-006, and CBT-004, with ongoing Phase 3 trials and partnerships established around April 2020. The company has raised additional capital in later rounds, including a Series C of $130M in 2022, bringing total funding to $171.26M across three rounds with investors like Grand Pharmaceutical and others. As of mid-2025, Cloudbreak holds numerous patents for its core products and is advancing clinical programs toward regulatory submissions in 2026.
Oct-18Series AHY Capital$16M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cloudbreak Pharma

When was Cloudbreak Pharma founded?Cloudbreak Pharma was founded in 2020.
Where is Cloudbreak Pharma headquartered?Cloudbreak Pharma is headquartered in United States.
How many employees does Cloudbreak Pharma have?As of today, Cloudbreak Pharma has over 51 employees.
Is Cloudbreak Pharma publicly listed?Yes, Cloudbreak Pharma is a public company listed on HKEX.
What is the stock symbol of Cloudbreak Pharma?Cloudbreak Pharma trades under 02592 ticker.
When did Cloudbreak Pharma go public?Cloudbreak Pharma went public in 2025.
Who are competitors of Cloudbreak Pharma?Cloudbreak Pharma main competitors include Biosyent, Invivyd, Humacyte, Sutro Biopharma, Starpharma, PolyPid, Scancell, Biomm, IMBiologics, Atrium Therapeutics.
What is the current market cap of Cloudbreak Pharma?Cloudbreak Pharma's current market cap is $140M.
Is Cloudbreak Pharma profitable?No, Cloudbreak Pharma is not profitable.
How many companies Cloudbreak Pharma has acquired to date?Cloudbreak Pharma hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cloudbreak Pharma has invested to date?Cloudbreak Pharma hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cloudbreak Pharma

Lists including Cloudbreak Pharma

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial